Infanrix IPV-GlaxoSmithKline-meningococcal meningitis-Haemophilus influenzae type b infection-pneumococcal infection

This entry refers to a combination vaccination regimen developed and studied by **GSK** (GlaxoSmithKline), involving the co-administration of **Infanrix IPV** (a quaternary vaccine against diphtheria, tetanus, pertussis, and poliomyelitis) with other conjugate vaccines to provide broad protection against **meningococcal serogroup C**, ***Haemophilus influenzae* type b (Hib)**, and **pneumococcal** infections. The regimen typically includes **Menitorix** (a combined Hib-MenC conjugate vaccine) and a **pneumococcal conjugate vaccine** (such as GSK's **Synflorix** or Pfizer's **Prevenar**). Clinical studies, including Phase 3 persistence trials, have evaluated the long-term antibody levels and booster responses in children who received these vaccines in their primary series. Although the name specifically mentions Infanrix IPV, related clinical trial arms often utilize **Infanrix Hexa**, which incorporates protection against **Hepatitis B**.

Brand names

Infanrix IPVMenitorixSynflorixPrevenarInfanrix Hexa

Other names

DTaP-IPV + Hib-MenC + PCVInfanrix IPV + Menitorix + Synflorix